好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Mortality and Long Term Outcome after Spontaneous Intracerebral Hemorrhage
Cerebrovascular Disease and Interventional Neurology
P5 - Poster Session 5 (5:30 PM-6:30 PM)
3-040

This study aimed to investigate the 30-day mortality and long-term outcomes following Spontaneous intracerebral haemorrhage (SICH) in a Tunisian population.

SICH is the second most common type of stroke (15%), with potentially devastating mortality and functional outcome.

We conducted a retrospective study at the department of Neurology at Habib Bourguiba hospital between January 2010 and December 2016. We evaluate possible predictors of 30-day mortality considering clinical and para-clinical parameters. We also applied modified Rankin scale (mRS) to evaluate functional outcome at 12 months. Poor functional outcome was defined as mRS≥3. The rate of recurrent SICH was also determined.

We identified 332 patients with SICH. The mean age was 68.4±13.3 years (18-93 years) and patients were predominantly male (62%). The 30-day mortality was 17.2%. Predictors of mortality were Glasgow coma scale (GCS) ≤12 (P=0.009), systolic blood pressure (SBP) (P=0.003), ICH volume ≥30cc (P=0.02), intraventricular hemorrhage (P<0.001), mass effect (P<0.001) and C reactive protein (CRP) (P=0.007). In multivariate analysis, only SBP≥160 mm Hg (Odds ratio (OR) =2.9, 95% confidence interval (CI) =1.1-7.8, P =0.03) and CRP≥15mg/L (OR =2.8, 95% CI =1.1-7, P= 0.02) were significant predictors for the 30-day mortality. At 12 months, 50% of patients who survived the first 30 days had a persistently poor functional status. Hypertension (P=0.02), infratentorial hematoma location (P=0.04) and mass effect (P=0.01) were associated with poor functional outcome at 1 year. After a mean follow-up of 20.9±14.8 months (6-45 months), 2.1% of patients had recurrent ICH.

We provide data on the mortality and long-term outcome of SICH in Tunisian patients. Those who survived had poor functional outcome and were at risk of recurrent ICH.
Authors/Disclosures

PRESENTER
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Chokri A. Mhiri, MD (Habib Bourguiba Hospital) Prof. Mhiri has received personal compensation for serving as an employee of Hikma. Prof. Mhiri has received personal compensation for serving as an employee of Sanofi Genzyme. Prof. Mhiri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Prof. Mhiri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche.